CN Patent

CN110950872A — 制备靶向抗癌药avapritinib的方法

Assigned to Wuhan Jiuzhou Yumin Medical Technology Co ltd · Expires 2020-04-03 · 6y expired

What this patent protects

本发明涉及一种制备靶向抗癌药avapritinib的方法。本路线采用现有容易获取得到的中间体作为起始原料，其对氨基进行Boc保护后再卤代反应，有效提高了卤代反应的产率，避免产生亚胺上的卤代副产物。

USPTO Abstract

本发明涉及一种制备靶向抗癌药avapritinib的方法。本路线采用现有容易获取得到的中间体作为起始原料，其对氨基进行Boc保护后再卤代反应，有效提高了卤代反应的产率，避免产生亚胺上的卤代副产物。

Drugs covered by this patent

Patent Metadata

Patent number
CN110950872A
Jurisdiction
CN
Classification
—
Expires
2020-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Jiuzhou Yumin Medical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.